EH
HUMA icon

Equitable Holdings’s Humacyte HUMA Stock Holding History

Equitable Holdings’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6K Buy
20,000
+5,000
+33% +$4.63K ﹤0.01% 1792
2026
Q1 		$14.4K Hold
15,000
– – ﹤0.01% 1679
2025
Q4 		$14.4K Sell
15,000
-1,700
-10% -$2.41K ﹤0.01% 1571
2025
Q3 		$29.1K Buy
+16,700
New +$32.7K ﹤0.01% 1519

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Equitable Holdings's HUMA Position: Q2 2026 in Review

Equitable Holdings increased its Humacyte (HUMA) stake by 33% in Q2 2026, buying an estimated $4.63K and bringing the position to 20,000 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1792.

Equitable Holdings first reported a position in HUMA in Q3 2025 and has held it in 4 quarters since. The position peaked at $29.1K in Q3 2025. 163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Equitable Holdings held 20,000 shares of Humacyte worth $15.6K as of Q2 2026.
  • Equitable Holdings bought 5,000 Humacyte shares in Q2 2026, an estimated $4.63K.
  • Humacyte made up ﹤0.01% of Equitable Holdings's portfolio in Q2 2026, its #1792 holding.
  • Equitable Holdings first reported a position in Humacyte in Q3 2025 and has held it in 4 quarters since.
  • Equitable Holdings's Humacyte position peaked at $29.1K in Q3 2025.
  • 163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Equitable Holdings's 13F filing for Q2 2026, filed 17 Aug 2026.